Emerging Challenges in Primary Care: Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
|
|
- Shawn Parsons
- 5 years ago
- Views:
Transcription
1 Emerging Challenges in Primary Care: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
2 Faculty Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell University Past President, Association of Black Cardiologists Medical Director, Queens Heart Institute Rosedale, NY Seth J. Baum, MD, FACC, FAHA, FACPM, FNLA, FASPC President & CMO Preventive Cardiology Excel Medical Clinical Trials Boca Raton, FL Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Professor of Medicine, Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA 2
3 Faculty Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate Past Chairman of the Board, Association of Black Cardiologists Director of Nuclear Imaging, Sharp Rees-Stealy Medical Group San Diego, CA David Montgomery, MD, PhD, FACC Preventive Cardiologist Piedmont Heart Institute Atlanta, GA Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology Director, UCLA Barbra Streisand Women s Heart Health Program Los Angeles, CA 3
4 Disclosures Ola Akinboboye, MD, MPH, MBA has no relevant financial relationships to disclose. Seth J. Baum, MD, FACC, FAHA, FACPM, FNLA, FASPC serves on the scientific advisory board for Sanofi, Amgen, Regeneron, and Akcea Therapeutics. Dr. Baum also serves as a consultant for Sanofi, Amgen, Akcea, Novo Nordisk, Regeneron, Cleveland Heart Labs, GLG Group, and Guidepoint Global. Dr. Baum is a national speaker for Amgen, Aralez, Boehringer Ingelheim, and Akcea and also serves as a speaker for Novo Nordisk. Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH serves as a consultant for Amgen, Boehringer Ingelheim, Sanofi, Novartis, and Quantum Genomics. 4
5 Disclosures Robert L. Gillespie, MD, FACC, FASE, FASNC serves as a consultant and speaker for Boston Scientific. David Montgomery, MD, PhD, FACC serves as a speaker for Novartis. Karol E. Watson, MD, PhD serves as a consultant for Amgen, Bayer, Boehringer Ingelheim, and Kowa. 5
6 Learning Objectives 1. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes. 2. Discuss current guidelines and recommendations for the management of hyperlipidemia in high risk patients. 3. Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk. 4. Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss strategies to overcome them. 6
7 PRE-TEST QUESTIONS 7
8 Pre-test ARS Question 1 How confident are you in your ability to determine which patients may benefit from use of a PCSK9 inhibitor? 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 8
9 Pre-test ARS Question 2 How often do you consider non-statin therapies for patients with high ASCVD risk and LDL-C not at recommended target, despite use of maximally tolerated statin? 1. Never 2. Rarely 3. Sometimes 4. Frequently 5. Always 9
10 Pre-test ARS Question 3 Approximately how many patients with hyperlipidemia do you see on a weekly basis, in any clinical setting? 1. None > 25 10
11 Statin Effects on Vascular Events Endpoint Events (%) Treatment Control Rate Ratio (CI) Non-fatal MI 2001 (4 4) 2769 (6 2) 0 74 ( ) CHD death 1548 (3 4) 1960 (4 4) 0 81 ( ) Any major coronary event 3337 (7 4) 4420 (9 8) 0 77 ( ) CABG 713 (3 3) 1006 (4 7) 0 75 ( ) PTCA 510 (2 4) 658 (3 1) 0 79 ( ) Unspecified 1397 (3 1) 1770 (3 9) 0 76 ( ) Any coronary revascularisation 2620 (5 8) 3434 (7 6) 0 76 ( ) Haemorrhagic stroke 105 (0 2) 99 (0 2) 1 05 ( ) Presumed ischaemic stroke 1235 (2 8) 1518 (3 4) 0 81 ( ) Any stroke 1340 (3 0) 1617 (3 7) 0 83 ( ) Any major vascular event 6354 (14 1) 7994 (17 8) 0 79 ( ) CTT. Lancet : Favors statin 11
12 Reduction in Stroke Risk With Statin Therapy 0 CARE (N = 4159) LIPID (N = 9014) MIRACL (N = 3086) Meta-analysis (N = 21,303) HPS (N = 20,536) Risk Reduction Prava 40mg -32% P = 0.03 Prava 40mg -19% P = Atorva 40mg Lova Prava Simva -31% P = 0.03 Simva 40mg -27% 2P < % P = Plehn JF, et al. Circulation. 1999;99: ; The LIPID Study Group. N Engl J Med. 1998;339: ; Schwartz GG, et al. JAMA. 2001;285: ; Ross SD, et al. Arch Int Med. 1999;159: ; Fox R. Circulation. 2001;104:e9051. Prava = Pravastatin Atorva = Atorvastatin Simva = Simvastatin Lova = Lovastatin 12
13 An underappreciated benefit of statin therapy is stroke reduction 13
14 2013 ACC-AHA Cholesterol Guidelines Stone NJ et al. Circulation. 2014;129:S
15 Pre-test ARS Question 4 70-year-old woman, 15-year history of hypertension, 10- year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd After reviewing the brief scenario above, please rate this statement as consistent with or not consistent with best clinical practice: Switch to atorvastatin 80 mg: 1. Yes, it is consistent 2. No, it is not consistent 15
16 ACC/AHA Statin Benefit Groups Secondary Prevention Clinical ASCVD Primary Prevention LDL-C > 190 mg/dl Diabetes Mellitus Primary Prevention > 7.5% 10-yr ASCVD risk Age < 75: High-intensity statin Age > 75: Moderate-intensity statin High-intensity statin 10-yr risk < 7.5%: Moderate-intensity statin 10-yr risk > 7.5%: High-intensity statin Consider moderate or high intensity statin Stone NJ et al. Circulation. 2014;129:S
17 High Intensity Statin Daily dose lowers LDL-C ~50% Intensity of Statin Therapy Moderate Intensity Statin Daily dose lowers LDL-C 30% -50% Low Intensity Statin Daily dose lowers LDL-C <30% Atorvastatin (40 )-80 mg Rosuvastatin 20 (40) mg Atorvastatin 10 (20) mg Rosuvastatin (5) 10 mg Simvastatin mg Pravastatin 40 (80) mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2-4 mg Simvastatin 10 mg Pravastatin mg Lovastatin 20 mg Fluvastatin mg Pitavastatin 1 mg Stone NJ et al. Circulation. 2014;129:S
18 The intensity of lipid-lowering therapy should match the intensity of risk 18
19 Inter-patient Variability in Response to Statins The graph below shows dramatic inter-individual variability in response to a statin (Atorvastatin 10 mg daily) Pedro-Botet J et al. Atherosclerosis 158 (2001)
20 Even though statins are robust LDL lowering drugs, there is significant inter-patient variability in statin response 20
21 Rationale for Pushing LDL-C Levels Even Lower Meta-analysis of 38,153 patients from 8 randomized statin trials LDL-C (mg/dl) < < < < <75 <50 LDL-C Levels and Risk of CV Events Adjusted Hazard Ratio 95% CI Boekholdt SM, et al. JACC. 2014;64(5): Event Rate (%) Major CV and Coronary Event Rates vs Various LDL-C Levels 4.4 <50 Major Coronary Events Major CV Events >190 LDL-C (mg/dl) 21
22 Non-statin Therapies The 2013 ACC-AHA cholesterol guidelines were intentionally vague on the use of non-statin therapy in addition to statins To offer clinicians more guidance, the American College of Cardiology convened Expert Consensus Decision Pathway committees to answer the questions In what patient populations should nonstatin therapies be considered? Which agents or therapies should be considered? Lloyd-Jones D et. al. J Am Coll Cardiol. 2016;67(5):
23 Pre-test ARS Question 5 70-year-old woman, 15-year history of hypertension, 10- year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd After reviewing the brief scenario above, please rate this statement as consistent with or not consistent with best clinical practice: Add ezetemibe: 1. Yes, it is consistent 2. No, it is not consistent 23
24 Pre-test ARS Question 6 70-year-old woman, 15-year history of hypertension, 10-year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd Ezetimibe is added. Six months later, LDL-C is 72 mg/dl. After reviewing the brief scenario above, please this statement as consistent with or not consistent with best clinical practice: Add PCSK9 inhibitor: 1. Yes, it is consistent 2. No, it is not consistent 24
25 Guidance on Use of Nonstatin Therapy All patients with ASCVD on statin Primary: >50% reduction in LDL-C Secondary (may consider): LDL-C <70 mg/dl Non-HDL-C <100 mg/dl Lloyd-Jones DM, et al. JACC. 2017;70(14): Ezetimibe or a PCSK9 inhibitor are the only non-statins recommended 25
26 IMPROVE-IT Trial 18,144 patients with recent ACS simvastatin 40 mg vs. simvastatin 40 mg + ezetimibe 10 mg Simvastatin alone (median LDL 69 mg/dl) Event rate % Simvastatin + ezetimibe (median LDL 54 mg/dl) RRR = 6% NNT = 50 Christopher Cannon et. al. N Engl J Med 2015; 372:
27 Questions to Consider 27
28 PCSK9 (Proprotein convertase subtilisin/kexin type 9) A secreted protein which targets the LDL receptor for degradation Gain of function mutations cause high LDL-C Loss of function mutations cause low LDL-C Inhibition lowers LDL-C levels Up-regulated by statin therapy 28
29 How is cholesterol removed from blood? LIVER Circulating LDL particles (which contain a large ApoB protein) are grabbed by an LDL receptor 29
30 How is cholesterol removed from blood? LIVER The entire complex is then internalized into the hepatocyte for LDL destruction 30
31 How is cholesterol removed from blood? Then the LDL particle is destroyed LIVER As the LDL particle is being destroyed, the LDL receptor migrates back to the hepatocyte cell surface so that it can grab more LDL molecules 31
32 How is cholesterol removed from blood? When PCSK9 is present, however, the LDL receptor gets stuck before it adheres to LDL and cannot migrate back to the surface LIVER It therefore gets destroyed along with the LDL And surface LDL receptors are depleted from the cell surface causing a rise in plasma levels of LDL particles and LDL-C 32
33 The theory behind PCSK9 inhibitors LIVER X If PCSK9 is inhibited, the LDL receptor can migrate back to the cell surface And surface LDL receptors will be restored so they can degrade LDL particles and lower serum cholesterol 33
34 Pre-test ARS Question 7 In the FOURIER trial, what was the numberneeded-to-treat to prevent an instance of the primary outcome (major cardiovascular events) with evolocumab compared to placebo?
35 Fourier Trial Design - Evolocumab 27,564 high-risk, stable patients with established CV disease (prior MI, prior stroke, or symptomatic PAD) Screening, Lipid Stabilization, and Placebo Run-in High or moderate intensity statin therapy (± ezetimibe) Evolocumab SC 140 mg Q2W or 420 mg QM LDL-C 70 mg/dl or non-hdl-c 100 mg/dl RANDOMIZED DOUBLE BLIND Placebo SC Q2W or QM Sabatine MS et al. Am H J 2016; 173: Follow-up ~ 3 years 35
36 Fourier Trial Lipid Results Placebo LDL Cholesterol (mg/dl) % mean reduction, P< Absolute reduction: 56 mg/dl (95%CI 55-57) (median LDL on Evolocumab 30 mg/dl, IQR mg/dl) Weeks Sabatine MS et al. Am H J 2016; 173:
37 Fourier Trial: Primary Outcome 16% 14% 12% 10% 8% 6% 4% 2% 0% Placebo Evolocumab 15% RRR NNT = Sabatine MS et al. N Engl J Med 2017; 376: Months 37
38 Fourier Trial: MI/Stroke/CV Death 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% Placebo Evolocumab 20% RRR NNT = 74 0% Months Sabatine MS et al. N Engl J Med 2017; 376:
39 Pre-test ARS Question 8 In the ODYSSEY trial, what was the relative risk reduction in the primary outcome (major cardiovascular events) with alirocumab compared to placebo? 1. 5% 2. 15% 3. 25% 4. 35% 39
40 Odyssey Outcomes Trial Design 18,924 post ACS patients (1-12 months) Run-in period of 2-16 weeks on high-intensity or maximum tolerated dose of atorvastatin or rosvastatin At least one lipid entry criterion met Alirocumab SC Q2W RANDOMIZED DOUBLE BLIND Placebo SC Q2W ACC Scientific Sessions 2018 Follow-up: event driven 40
41 Odyssey Trial Lipid Results Upward drift likely due to protocol mandated discontinuation of therapy for LDL < 30 mg/dl ACC Scientific Sessions
42 Odyssey Trial Primary Outcome RRR = 15% NNT = 63 ACC Scientific Sessions
43 Odyssey: All Cause Mortality RRR = 15% NNT = 166 ACC Scientific Sessions
44 Indication Dosing Approved PCSK9 Inhibitors Alirocumab Adjunct to diet and maximumtolerated statin for adults with HeFH or clinical ASCVD who require additional lowering of LDL-C mg SQ Q2W 300 mg SQ monthly Evolocumab To reduce risk of CVE in adults with established CVD Adjunct to diet, alone or in combination with other LLT, for adults with primary hyperlipidemia (including HeFH) to reduce LDL-C Adjunct to diet and other LDL-lowering therapies in patients with HoFH who require additional lowering of LDL-C 140 mg SC Q2W 420 mg SC monthly How supplied Side effects Single-dose prefilled pens or syringes 75-mg/mL or 150-mg/mL Nasopharyngitis Injection-site reactions Hypersensitivity reactions Single-use prefilled syringe or autoinjector 1 ml of 140-mg/mL or 420 mg/3.5 ml Nasopharyngitis Injection-site reactions Hypersensitivity reactions Accessed May 8, Accessed May
45 You will see lower LDL levels with PCSK-9 inhibitors than you ve ever seen before 45
46 FOURIER Trial Efficacy and Safety in Patients With LDL-C <10 mg/dl Cardiovascular Efficacy Safety LDL > 100 LDL < 10 LDL > 100 LDL < Percent (%) Percent (%) CVD, MI, Stroke, UA, Cor Revasc CVD, MI, Stroke 0 Serious AE AE (Drug Discontinued) Giugliano RP, et al. Lancet. 2017;390(10106):
47 Even LDL-C levels < 10 appear to be safe (and efficacious) 47
48 When to Consider a PCSK9 Inhibitor Patient Type ASCVD without comorbidities ASCVD with comorbidities 21 years with ASCVD and baseline LDL-C 190 mg/dl 21 years without ASCVD and baseline LDL-C 190 mg/dl years without ASCVD and with DM and baseline LDL-C mg/dl years without ASCVD or DM and baseline LDL-C mg/ dl LDL-C Reduction on Maximally Tolerated Statin <50% LDL-C reduction or LDL-C >70 mg/dl <50% LDL-C reduction or LDL-C >70 mg/dl <50% LDL-C reduction or LDL-C >70 mg/dl <50% LDL-C reduction or LDL-C >100 mg/dl <50% LDL-C reduction or LDL-C >100 mg/dl <50% LDL-C reduction or LDL-C >100 mg/dl Therapy Recommendation Ezetimibe 1st; PCSK9 inhibitor 2nd Ezetimibe * or PCSK9 inhibitor Ezetimibe* or PCSK9 inhibitor Ezetimibe* or PCSK9 inhibitor Ezetimibe or bile acid sequestrant Ezetimibe or bile acid sequestrant Lloyd-Jones DM, et al. JACC. 2017;70(14)
49 A Quantitative Approach to Adding Nonstatin Therapy Robinson JG, et al. JACC. 2016;68(22):
50 A Quantitative Approach to Adding Nonstatin Therapy Very high risk: >30% 10-year ASCVD risk Clinical ASCVD + diabetes Clinical ASCVD + familial hypercholesterolemia Clinical ASCVD + poorly controlled risk factors Recent acute coronary syndrome (<3 months) Clinical ASCVD + polyvascular disease Clinical ASCVD + age >65 years Clinical ASCVD + multiple recurrent events Clinical ASCVD + elevated Lp(a) High risk: 20%-<30% 10-year ASCVD risk Clinical ASCVD without high-risk features Familial hypercholesterolemia Moderate risk: 10%-<20% 10-year ASCVD risk With or without DM Robinson JG, et al. JACC. 2016;68(22):
51 Access to PCSK9 Inhibitors Baum et al. (44,234 prescriptions) 1-83% of PCSK9 inhibitor prescription rejected initially; 57% rejected ultimately - Patients with PCSK9 prescriptions approved were more likely to be on high-intensity statin + ezetimibe Navar et al. (prescriptions for 45,029 patients) 2-79% rejected within 24 hours; 53% rejected ultimately - Rejection rates: 33% 78% for commercial payers; 38% 84% for government insurance programs; 33% 75% across PBMs - 35% of filled prescriptions were abandoned at the pharmacy 1. Baum SJ, et al. Presented at the 66 th Scientific Session of the ACC, Washington, DC, March 17-19, Abstract Navar AM, et al. Presented at the 66 th Scientific Session of the ACC, Washington, DC. March 17-19, Abstract
52 PCSK9 Inhibitor Support Programs Alirocumab programs 1 - Copay cards for $0 per month with annual cap of $5,500 for eligible patients with commercial insurance - Low income subsidy program for Medicare patients - Patient assistance program to provide free medication to eligible patients for up to 12 months which can be renewed - Insurance specialist available to assist with prior authorization Evolocumab programs 2 - Copay card $5 for eligible patients with commercial insurance - Insurance specialist available to offer assistance with coverage issues 1. Accessed September 18, Accessed May 18,
53 Common Reasons for PCSK9 Denial: A Veritable Laundry List Patient has not tried ezetimibe Re-challenge with statin not documented in statin-intolerant patient Patient has not tried a bile acid sequestrant LDL <100 mg/dl with ASCVD or <130 mg/dl without ASCVD Requires 80% compliance in fill history from pharmacy over 12-month period Nutrition intervention not documented Triglycerides >400 mg/dl Kaufman TM, Duell PB, et al. Circ Res. 2017;121(5):
54 Common Reasons for PCSK9 Denial: A Veritable Laundry List Exercise and weight management regimen not documented Requires confirmation of FH with genetic testing Criteria for definite FH not documented Indication for PCSK9 inhibitor not clearly documented Failure to submit office notes or labs with prior authorization request No statement that patient will continue to receive maximally tolerated statin ASCVD criteria not met Kaufman TM, Duell PB, et al. Circ Res. 2017;121(5):
55 Required Documentation for PCSK9 Prior Authorization (PA) Detailed medical history including prior and current medications, doses, dates of administration, reasons for discontinuation Family history of hypercholesterolemia and/or CAD Physical exam for xanthomas and DLCN score (for patients with FH) AHA criteria for diagnosis of FH Kaufman TM, Duell PB, et al. Circ Res. 2017;121(5):
56 Required Documentation for PCSK9 Prior Authorization (PA) Most recent lab results ( 30 days) including lipid panel and lipoprotein (a) Highest documented LDL-C concentration (ideally off treatment) Evidence of subclinical atherosclerosis (coronary artery calcium, CIMT, ankle brachial index) or clinical ASCVD (MI, stroke, angina, angiographic evidence, ischemia testing, arterial revascularization) Clear specification of diagnosis for which PCSK9 inhibitor therapy is being prescribed Kaufman TM, Duell PB, et al. Circ Res. 2017;121(5):
57 Pre-test ARS Question 9 Which of the following strategies has demonstrated high rates of approval for the use of PCSK9 inhibitors? 1. Partner with prior-approval consultants 2. Discontinue use of other non-statin therapies prior to prescribing PCSK9 inhibitor 3. Employ multidisciplinary team to coordinate approval process 4. Refer patients to center with extensive experience with PCSK9 inhibitors 57
58 Strategies to Improve PCSK9 Inhibitor Access: A Team-Based Approach Have dedicated team to deal with prior authorizations, appeals, re-appeals, and peer-to-peer reviews Multidisciplinary team of physicians, a nurse, a medical assistant, a clinical pharmacist, and a physician assistant (the PCSK9 inhibitor Clinic ) - Coordinator oversees the approval process, provides injection training, and arranges longitudinal management and surveillance - 92% success rate (n=142/153) Key to successful PCSK9 inhibitor PA approval Meticulous documentation of all data required for PA Kaufman TM, Duell PB, et al. Circ Res. 2017;121(5):
59 ACC PSCK9 Prior Authorization Reporting Tool (PART) Available at: Accessed 5/7/18 59
60 Statins are still the mainstay of lipid-lowering therapy 60
61 Meta-analysis 14 Statin Trials (90,056 participants) For each 39 mg/dl LDL-C lowering with statins 12% reduction in all-cause mortality (P<0.0001) 19% reduction in coronary mortality (P<0.0001) 23% reduction in MI and coronary death (P<0.0001) 24% reduction in revascularizations (P<0.0001) 17% reduction in fatal or non-fatal stroke (P<0.0001) 21% reduction in any major vascular event (P<0.0001) Adapted from Baigent C et al. Cholesterol Treatment Trialists (CTT) Collaborators. Lancet 2005; 366:
62 Nonadherence to Statin Treatment Begins Early Adapted from cohort study in Ontario, Canada (N=85,020) Jackevicius et al. JAMA. 2002;288:
63 Patients Non-adherent to Statin Therapy Have Poorer Outcomes Adherent Nonadherent Patients With MI (%) P= P= P= Total Blackburn DF, et al. Pharmacotherapy. 2005;25: Patients <65 Years Patients 65 Years 63
64 Patients should know that nonadherence to statin therapy may be associated with significant morbidity 64
65 Hyperlipidemia LDL-C is the target of lipid therapy and statins are the mainstay of treatment Response to statins is variable and influenced by many factors including genetic factors New therapies are emerging for treatment of hyperlipidemia Patient populations at highest CHD risk may potentially benefit greatly from such therapies 65
66 POST-TEST QUESTIONS 66
67 Post-test ARS Question 1 After completing this activity, how confident are you now in your ability to determine which patients may benefit from use of a PCSK9 inhibitor? 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 67
68 Post-test ARS Question 2 After completing this activity, how often do you now intend to consider non-statin therapies for patients with high ASCVD risk and LDL-C not at recommended target, despite use of maximally tolerated statin? 1. Never 2. Rarely 3. Sometimes 4. Frequently 5. Always 68
69 Post-test ARS Question 3 70-year-old woman, 15-year history of hypertension, 10- year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd After reviewing the brief scenario above, please rate this statement as consistent with or not consistent with best clinical practice: Switch to atorvastatin 80 mg: 1. Yes, it is consistent 2. No, it is not consistent 69
70 Post-test ARS Question 4 70-year-old woman,15-year history of hypertension, 10- year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd After reviewing the brief scenario above, please this statement as consistent with or not consistent with best clinical practice: Add ezetemibe: 1. Yes, it is consistent 2. No, it is not consistent 70
71 Post-test ARS Question 5 70-year-old woman,15-year history of hypertension, 10-year history of dyslipidemia NSTEMI 1 year ago, LDL-C is 88 mg/dl Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd Ezetimibe is added. Six months later, LDL-C is 72 mg/dl. After reviewing the brief scenario above, please rate this statement as consistent with or not consistent with best clinical practice: Add PCSK9 inhibitor: 1. Yes, it is consistent 2. No, it is not consistent 71
72 Post-test ARS Question 6 In the FOURIER trial, what was the numberneeded-to-treat to prevent an instance of the primary outcome (major cardiovascular events) with evolocumab compared to placebo?
73 Post-test ARS Question 7 In the ODYSSEY trial, what was the relative risk reduction in the primary outcome (major cardiovascular events) with alirocumab compared to placebo? 1. 5% 2. 15% 3. 25% 4. 35% 73
74 Post-test ARS Question 8 Which of the following strategies has demonstrated high rates of approval for the use of PCSK9 inhibitors? 1. Partner with prior-approval consultants 2. Discontinue use of other non-statin therapies prior to prescribing PCSK9 inhibitor 3. Employ multidisciplinary team to coordinate approval process 4. Refer patients to center with extensive experience with PCSK9 inhibitors 74
75 Questions 75
Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Emerging Challenges in Primary Care: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell
More informationManaging Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Emerging Challenges in Primary Care: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell
More informationManaging Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More information10/4/17. Emerging Challenges in Primary Care: 2017
Emerging Challenges in Primary Care: 2017 New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice 1 Faculty Jan Basile, MD Professor of Medicine Seinsheimer
More informationEmerging Challenges in Primary Care: New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice
Emerging Challenges in Primary Care: 2017 New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice 1 Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationPamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationPraluent (alirocumab)
Praluent (alirocumab) Policy Number: 5.01.600 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationPatient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More information2017 Update in Internal Medicine: Clinical Dyslipidemia Update
2017 Update in Internal Medicine: Clinical Dyslipidemia Update Erin E. Kershaw, M.D. Chief, Division of Endocrinology Associate Professor of Medicine Certified in Endocrinology, Diabetes, and Metabolism
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationGoal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, d Double-blind, bli Placebo- Controlled Study Evan A. Stein 1, David Sullivan 2,
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationEvan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationPatient List Inquiries
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient List Inquiries in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPatient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION
ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationClinical Policy: Alirocumab (Praluent) Reference Number: CP.CPA.268 Effective Date: Last Review Date: 11.17
Clinical Policy: (Praluent) Reference Number: CP.CPA.268 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More information